Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 2, Issue 13, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3000406
Keywords
-
Categories
Funding
- NCI NIH HHS [P30 CA046592, P01 CA039542, P30 CA046592-19, P01-CA039542-20, P01 CA039542-20, P30CA46592] Funding Source: Medline
- NHLBI NIH HHS [RC1-HL-101102, RC1 HL101102, RC1 HL101102-01] Funding Source: Medline
Ask authors/readers for more resources
Graft-versus-host disease (GVHD), the major complication of allogeneic bone marrow transplantation, affects the skin, liver, and gastrointestinal tract. There are no plasma biomarkers specific for any acute GVHD target organ. We used a large-scale quantitative proteomic discovery procedure to identify biomarker candidates of skin GVHD and validated the lead candidate, elafin, with enzyme-linked immunosorbent assay in samples from 492 patients. Elafin was overexpressed in GVHD skin biopsies. Plasma concentrations of elafin were significantly higher at the onset of skin GVHD, correlated with the eventual maximum grade of GVHD, and were associated with a greater risk of death relative to other known risk factors (hazard ratio, 1.78). We conclude that elafin has significant diagnostic and prognostic value as a biomarker of skin GVHD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available